- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.02. | Journey Medical Corporation (DERM): A Bull Case Theory | 1 | Insider Monkey | ||
| JOURNEY MEDICAL Aktie jetzt für 0€ handeln | |||||
| 05.02. | Journey Medical Corp - 8-K, Current Report | - | SEC Filings | ||
| 24.01. | Minot Light Capital's Largest Performance Detractor in Q4: Journey Medical (DERM) | 2 | Insider Monkey | ||
| 16.12.24 | Journey Medical Co. (NASDAQ:DERM) Sees Large Increase in Short Interest | 3 | MarketBeat | ||
| 13.11.24 | Journey Medical GAAP EPS of -$0.12 beats by $0.03, revenue of $14.63M beats by $0.24M | 1 | Seeking Alpha | ||
| 12.11.24 | Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights | 131 | GlobeNewswire (Europe) | U.S. FDA approved Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults; launch expected in late Q1 or early Q2 of 2025... ► Artikel lesen | |
| 12.11.24 | Journey Medical Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.11.24 | FDA approves Journey Medical's Emrosi to treat inflammatory lesions of rosacea | - | PMLiVE | ||
| 05.11.24 | FDA approves Journey Medical's rosacea treatment Emrosi | 1 | Pharmaceutical Technology | ||
| 04.11.24 | Journey Medical, with FDA nod, won't stop believing it can establish new rosacea standard of care | 3 | FiercePharma | ||
| 04.11.24 | What's Going On With Journey Medical Stock Today? | 2 | Benzinga.com | ||
| 04.11.24 | Journey Medical: FDA Approves Emrosi For Treatment Of Inflammatory Lesions Of Rosacea | 1 | RTTNews | ||
| 04.11.24 | Journey Medical Corporation Announces U.S. FDA Approval of Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea | 156 | GlobeNewswire (Europe) | SCOTTSDALE, Ariz., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and... ► Artikel lesen | |
| 04.11.24 | Journey Medical Corp - 8-K, Current Report | - | SEC Filings | ||
| 03.10.24 | Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference | 2 | GlobeNewswire (USA) | ||
| 01.10.24 | PVG Asset Management Corp Purchases New Holdings in Journey Medical Co. (NASDAQ:DERM) | 2 | MarketBeat | ||
| 09.09.24 | Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference | 1 | GlobeNewswire (USA) | ||
| 06.09.24 | Lake Street starts Journey Medical with Buy, sets stock target on product launch | 1 | Investing.com | ||
| 12.08.24 | Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights | 280 | GlobeNewswire (Europe) | New Drug Application for DFD-29 to treat rosacea under FDA review; PDUFA goal date of November 4, 2024 Total revenues for the second quarter ended June 30, 2024 were $14.9 million, a 14% increase... ► Artikel lesen | |
| 13.05.24 | Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights | 223 | GlobeNewswire (Europe) | New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Total revenues for the first quarter ended March 31, 2024 were $13.0 million, a 7%... ► Artikel lesen |
Seite:
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 24,975 | -0,26 % | Pfizer? Das ist die heißeste Biotech-Aktie 2025 | Die Pharmaindustrie steht vor einer Übernahmeoffensive, darauf deuten immer mehr Anzeichen hin. Ablaufende Patente und löchrige Pipelines zwingen große Player wie Pfizer zu Akquisitionen. Profiteure... ► Artikel lesen | |
| GILEAD SCIENCES | 110,66 | -0,02 % | MEDSIR & Debiopharm Announce the First Patient Dosed in the WIN-B Trial Exploring the Combination of Debio 0123 & Gilead's Trodelvy in Advanced Breast Cancer | WIN-B (NCT06612203) is a Phase Ib/II, multi-center investigator-initiated trial, evaluating the safety and preliminary efficacy of combining Debiopharm's selective WEE1 inhibitor, Debio 0123 and... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 461,65 | +0,09 % | Vertex Aktie: Strahlende Aussichten entwickeln sich! | Führende Köpfe des Biotechnologieunternehmens Vertex Pharmaceuticals Inc. haben kürzlich Aktien im erheblichen Umfang verkauft. Die Transaktion erfolgte zu einem Zeitpunkt, an dem die Vertex-Aktie eine... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 5,926 | +8,50 % | EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., Feb. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 6,105 | -5,05 % | Astria Therapeutics, Inc.: Astria Therapeutics beginnt Phase-3-Zulassungsstudie ALPHA-ORBIT zu Navenibart bei hereditärem Angioödem | -- Studie zum Nachweis der Wirksamkeit und Sicherheit der Verabreichung alle 3 und alle 6 Monate in einem 6-monatigen Behandlungszeitraum --
Astria Therapeutics, Inc. (Nasdaq: ATXS), ein biopharmazeutisches... ► Artikel lesen | |
| ROCKET LAB USA | 17,750 | -0,28 % | Rocket Lab legt Datum für 61. Electron-Start fest | ||
| OPKO HEALTH | 1,677 | +0,72 % | OPKO Health, Inc.: OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results | MIAMI, Feb. 27, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2024. Highlights from the... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 110,00 | 0,00 % | ROUNDUP: Ligand Pharma Slips To Loss In Q4; Confirms FY25 Outlook | WASHINGTON (dpa-AFX) - Biopharmaceutical company Ligand Pharmaceuticals, Inc. (LGND), while reporting a loss in its fourth quarter, compared to prior year's profit, on Thursday confirmed fiscal... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 133,65 | -0,07 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance | - Record total revenues of $4.1 billion in 2024 and $1.1 billion in 4Q24 -- Xywav® and Epidiolex® revenues grew 16% and 15% year-over-year, respectively, in 2024 -- Oncology revenues grew... ► Artikel lesen | |
| ROYALTY PHARMA | 32,370 | +0,22 % | Dividendenbekanntmachungen (21.02.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABRDN AUSTRALIA EQUITY FUND INC US0030111035 0,12 USD 0,1143 EUR ABRDN JAPAN EQUITY FUND INC US00306J1097 0,11 USD 0,1047 EUR ANGEL... ► Artikel lesen | |
| TG THERAPEUTICS | 32,480 | -1,20 % | TG THERAPEUTICS, INC. - 10-K, Annual Report | ||
| CATALYST PHARMACEUTICALS | 21,360 | +0,28 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | Full Year 2024 Total Revenues of $491.7 Million, Marking Another Year of Record Growth Full Year 2024 Total Revenues Grew 23.5% YoY, Driven by Strong Commercial Performance Q4 2024 Net... ► Artikel lesen | |
| CORBUS PHARMACEUTICALS | 6,900 | +3,76 % | William Blair starts Corbus stock with Outperform rating | ||
| CATALENT | 59,93 | 0,00 % | Ardena Holding NV.: Ardena Completes Acquisition of Advanced Drug Product Manufacturing Facility from Catalent and Expands Bioanalytical Services in North America | Ghent, Belgium, 4th February 2025
Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organization (CDMO) and bioanalytical Contract Research Organization (CRO) with facilities... ► Artikel lesen | |
| TALPHERA | 0,528 | +2,72 % | Talphera, Inc.: Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study | Submission of a Prior Approval Supplement for a reduction in the number of patients in the NEPHRO CRRT study is expected within the coming week
The FDA agreed to... ► Artikel lesen |
JOURNEY MEDICAL CORPORATION gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von -0,500 (-8,99 %) liegt der Kurs bei 5,060 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JOURNEY MEDICAL CORPORATION finden Sie auf Wallstreet Online.
